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Abstract Cross-contamination during or early after establish-
ment of a new cell line could result in the worldwide spread of
a misidentified cell line. Therefore, newly established cell
lines need to be authenticated by a reference standard method.
This study was conducted to investigate the authenticity of a
newly established epithelial cell line of human esophageal
squamous cell carcinoma (ESCC) called YM-1 using short
tandem repeat (STR) DNA profiling method. Primary human
ESCC epithelial cells were cultured from the fresh tumor tis-
sue of an adult female patient. Growth characteristics and
epithelial originality of YM-1 cells were studied. Genomic
DNA was isolated from YM-1 cells harvested at passage 22
and ESCC donor tumor sample on two different days to pre-
vent probable DNA contamination. STR profiling was per-
formed using AmpFℓSTR® Identifiler® Plus PCR
Amplification Kit. To address whether YM-1 cells undergo
genetic alteration as the passage number increases, STR pro-
filing was performed again on harvested cells at passage 51.
YM-1 cells grew as a monolayer with a population doubling
time of 40.66 h. Epithelial originality of YM-1 cells was con-
firmed using ICC/IF staining of cytokeratins AE1/AE3. The
STR profile of the ESCC donor tumor sample was the same
with YM-1 cells at passage 22. However, STR profile of the
donor tumor sample showed an off-ladder (OL) allele in their
D7S820 locus. Also, re-profiling of YM-1 cells at passage 51
showed a loss of heterozygosity (LOH) at D18S51 locus. This
suggests that long-term culture of cell lines may alter their
DNA profile. Comparison of the DNA fingerprinting results
in DSMZ, and ATCC STR profiling databases confirmed
unique identity of YM-1 cell line. This study provides an easy,
fast, and reliable procedure for authentication of newly
established cell lines, which helps in preventing the spread
of misidentified cells and improving the reproducibility and
validity of experiments, consequently.
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Introduction
Establishment and authentication of continuous cell lines
originated from human tumor tissues may be useful in
studying the cellular and molecular characteristics of the
same tumor [1] and minimizing the use of animal models
[2]. However, numerous warnings have emerged from the
literature concerning appropriate use of cell lines as model
systems [3, 4]. Cell line misidentification is one of the most
serious and persistent problems which often originates from
cross-contamination [5]. An estimated 36 % of cell lines
used in experiments have been misidentified or cross-
contaminated with other cell lines [6–8]. Scientific misrep-
resentations and invalid results are the most irrecoverable
outcomes of using misidentified cell lines during experi-
mental studies.
[6]. Cross-contamination may happen under several condi-
tions, including poorly controlled manipulation, sharing cul-
ture media and reagents, simultaneous manipulation of multi-
ple cultures, and mislabeling a flask or ampoule [5, 9, 10]
(ASN-0002). In addition, mitotically inactivated feeder cells,
xenografting and conditioned media may carry contaminating
cells if not properly eliminated [11].
Awareness of misidentification dates back to the 1950s
[10]. Stanley Gartler, for the first time, introduced the concept
of biochemical polymorphisms to distinguish human cell lines
on the basis of their isozyme expression [12]. DNA finger-
printing for cell authentication purposes, which was based on
polymorphisms in DNA sequences at given loci, was firstly
employed by Masters et al. and Thacker et al. [13, 14].
Sensitivity of DNA fingerprinting for cell authentication was
further improved by PCR-based short tandem repeat (STR)
typing [15]. STR profiling, which currently serves as an inter-
national reference standard for human cell line authentication,
is a rapid, reproducible, and standardized PCR-based method
[8]. Using this method, various polymorphic STR loci are
amplified, and the resulting PCR products are then resolved
by capillary electrophoresis [6]. The sized PCR products are
then converted into alleles with comparison to the standard
allelic ladders, and the assigned alleles are then converted into
numeric values which are used to create a baseline profile
[16]. Comparison of the STR profile with a reference standard
database determines whether or not a cell line is misidentified.
Cross-contamination of newly established cell lines
could result in the worldwide spread of misidentified cell
lines [7, 17]. To our knowledge, there have been no pub-
lished studies that recommend the authentication of newly
established cell lines prior to entering cell line collections
and general use by other researchers. This study was aimed
to investigate the authenticity of newly established ESCC
cell line called YM-1 and describe that authentication of
new cell lines can help prevent the worldwide spread of a
misidentified cell line, which, in turn, prevents obtaining of
misleading results.
Material and methods
Newly established YM-1 cell line and culture condition
Tumor specimen
A fresh tumor specimen was derived from a 50-year-old
Iranian woman (Turkmen race) with esophageal squamous
cell carcinoma. The specimen was resected from middle
intra-thoracic esophagus (30 cm from incisors) prior to che-
motherapy. The study was approved by the Ethics Committee
of Golestan University of Medical Sciences and written in-
formed consent was obtained from the patient.
A primary culture
Immediately after resection, tumor specimen was placed in a
15-ml conical centrifuge tube containing 5 ml of ice-cold
transport medium and transferred to the lab (≈30 min). A
small piece of tumor tissue (approximately 0.5 cm3) was fixed
in 10 % formalin for 24 h and processed for hematoxylin and
eosin (H&E) staining. Also, a small piece of tumor tissue
(approximately 0.5 cm3) was frozen at −70 °C for DNA
extraction.
Tumor tissue was washed five times in a Petri dish contain-
ing fresh, sterile ice-cold DBSSmedium and minced by cross-
cutting with two scalpels into small pieces as by size of 1 mm
3. The tissue pieces were then transferred into a 50-ml sterile
conical centrifuge tube containing 5 ml Trypsin-EDTA
Fig. 1 STR profiling process. After transferring the tumor sample to the
cell culture laboratory, primary cultures were performed. Two small
pieces of tumor sample were also stored for DNA extraction and
pathology examination. Then, STR profiling was performed, and the
data were analyzed by comparing with DSMZ and ATCC databases.
For more details, see the text. ESCC esophageal squamous cell
carcinoma, STR short tandem repeat, DSMZ Deutsche Sammlung von
Mikroorganismen und Zellkulturen, ATCC American type culture
collection
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(0.25 %) at room temperature. Supernatant was collected
(without centrifugation) every 15 min and replaced by
Trypsin-EDTA (0.25 %). The process was repeated several
times until the tissue was completely dispersed. The clump-
free cell suspension was decanted into another 50-ml sterile
conical centrifuge tube containing growth medium (RPMI
with 10 % FBS). The suspension was then centrifuged for
3 min at 1000 rpm. The supernatant was discarded, and the
cells were re-suspended in RPMI 1640medium supplemented
with 10 % FBS, penicillin G (100 U/ml), streptomycin
(100 μg/ml), gentamicin (2.6 μg/ml), and fungizone (2.5 μg/
μl). Finally, the cells were seeded in 25-cm2 culture flasks and
placed in a CO2 incubator at 37 °C. The flasks were
examined daily. One third of the medium in each flask
was replaced every 3 to 5 days by fresh culture medium.
Stromal fibroblast cells were diminished using the differ-
ential trypsinization method [18].
Growth characteristics of YM-1 cell line
Approximately, 3×104 YM-1 cells of passage 51 were seeded
into each well of 35-mm six-well dishes with 3 ml of growth
medium that was replaced every 2 days. The number of viable
cells was determined by the dye exclusion method every 24 h
for 10 days using the trypan blue staining. The growth curve
was plotted, and the doubling time was calculated from the
data obtained from the logarithmic phase of the growth curve
(Roth V. 2006 <http://www.doubling-time.com/compute.
php>).
Immunocytochemistry/immunofluorescence (ICC/IF)
staining of cytokeratins
Expression of cytokeratins was examined by ICC/IF staining
of YM-1 cells at passage 50 with pan-Cytokeratin (AE1/AE3)
(Santa Cruz Biotechnology Cat# sc-81714). YM-1 cells were
fixed with 4 % paraformaldehyde in PBS, permeabilized with
0.1 % Triton X-100 in PBS for 15 min, and blocked with 1 %
BSA in PBS for 45 min at room temperature. Samples were
incubated with primary antibody (1/100 in PBS) overnight at
4 °C. Sheep Anti Mouse Ig-Human Ads- FITC conjugated
(SINA BIOTECH Cat#SB-029921) (IgG polyclonal; 1/50)
was used as the secondary antibody. Cells were incubated
for 10 min in the diluted DAPI (1 μg/ml in PBS) as a
Fig. 4 Morphology of primary
cells. a Cells after dissociation of
human ESCC tumor. b Nervous-
like cells. c Epithelial-like cells
surrounded by stromal fibroblast
cells. d Epithelial cells after
passage 22. ×100
Fig. 3 Well-differentiated squamous cell carcinoma of esophagus. The
tumor consists of large cells and shows prominent keratinization. ×200
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Fig. 5 ICC/IF staining of
cytokeratins. The YM-1 cells
were strongly positive for
cytokeratins AE1/AE3 by ICC/IF.
Anti-AE1/AE3 positive (a), anti-
AE1/AE3 positive+DAPI (b),
negative control, anti-AE1/AE3
negative (c), and anti-AE1/AE3
negative+DAPI (d)
Fig. 2 Growth curve of YM-1
cells at the 51st passage
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counterstain, before visualization by inverted fluorescent mi-
croscope (Nikon Eclipse Ti).
DNA extraction
Genomic DNA of YM-1 cells (5×105) at passage 22 and their
donor tissue was purified using the High Pure PCR Template
Preparation Kit (Roche, Germany) in different days to prevent
cross-contamination according to the manufacturer’s instruc-
tions. DNA concentration was determined by Picodrop UV/
Vis Spectrophotometer (Picodrop Ltd, UK) at 260 nm. One
nanogram of DNA of each sample was used for STR
profiling.
STR profiling
To ensure that our cell line was authentic, STR profiling of
both YM-1 cell line and donor tissue was performed and com-
pared. Briefly, STR profiling procedure were as follows: 15
tetranucleotide repeat loci (D8S1179, D21S11, D7S820,
CSF1PO, D3S1358, TH01, D13S317, D16S539, D2S1338,
D19S433, vWA, TPOX, D18S51, D5S818, and FGA) and the
amelogenin gender-determining marker were amplified using
the AmpFℓSTR® Identifiler® Plus PCR Amplification Kit
(Applied Biosystems, USA) according to the manufacturer’s
instructions. Electrophoretic analysis was carried out using
ABI PRISM1 310 Genetic Analyzer (Applied Biosystems,
USA). After electrophoresis, the data were analyzed by the
Gene Mapper® ID-X Software v1.0 (Applied Biosystems,
USA) to categorize peaks according to their size in relation
to an internal standard allelic ladder.
Re-STR profiling of YM-1 cell line at passage 51
To address whether YM-1 cells undergo genetic alteration as
the passage number increases, STR profiling was implement-
ed again using the AmpFℓSTR® Identifiler® Plus PCR
Amplification Kit on harvested cells at passage 51.
Data analysis
STR data were analyzed using two online databases, a
German Collection of Microorganisms and Cell Cultures,
DSMZ, and ATCC STR database. After registration, our
STR data were entered to be matched with authenticated cell
lines listed in these databases.
Results
The whole process is summarized in Fig. 1. In this study, the
YM-1 cell line was established from a female patient with a
well-differentiated squamous cell carcinoma (Fig. 3) who had
not received chemotherapy, previously. Histological diagnosis
was determined on the basis of microscopic features of carci-
noma cells. Fibroblast cells appeared on the third day. Besides
fibroblast cells, abnormal cells were observed on the early
days of primary cell culture. Some of these cells were
nervous-like which were gradually eliminated (Fig. 4).
Initial epithelial-like cells were observed on the 11th day of
initial plating, but initial cell passage was performed 3 weeks
later. Stromal fibroblasts were eliminated by differential
trypsinization [19].
The YM-1 cells grew as an adherent monolayer with epi-
thelial features and nuclear abnormalities. These cells are now
(August 2015) at passage 53 and have been growing continu-
ously for more than 14 months. The growth curve of these
Fig. 6 The STR profile of YM-1
cell line. The figure shows the 16-
locus multiplex fingerprint of
YM-1 cell line at passage 22 (a)
and the presence of LOH at STR
locus D18S51 of these cells at
passage 51 (b). The LOH data
indicate deletion (arrow) of the
allele 10, resulting in apparent
homozygosity. STR loci are
indicated in boxes above
electropherogram; numbers of
repeat units are indicated below
the peaks. STR short tandem
repeat, LOH loss of
heterozygosity, A amelogenin
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Table 1 The STR profile of YM-1 cells at passages 22 and 51, and their donor tissue
Locus Chromosomal location Genotypes of samples
Tumor tissue YM-1 cells at
passage 22
YM-1 cells at
passage 51
Eight core loci
D5S818 5q21-31 8, 8 8, 8 8, 8
D7S820 7q11.21-22 11, OL 11, 12 11, 12
D13S317 13q22-31 11, 11 11, 11 11, 11
D16S539 16q24-qter 10, 12 10, 12 10, 12
CSF1PO 5q33.3-34 9, 9 9, 9 9, 9
TH01 11p15.5 8, 8 8, 8 8, 8
vWA 12p12-pter 16, 18 16, 18 16, 18
TPOX 2p23-2per 12, 12 12, 12 12, 12
Seven additional loci
D2S1338 2q35-37.1 20, 23 20, 23 20, 23
D3S1358 3p 15, 16 15, 16 15, 16
D8S1179 8p 12, 15 12, 15 12, 15
D18S51 18q21.3 10, 14 10, 14 LOH, 14
D19S433 19q12-13.1 14.2, 15.2 14.2, 15.2 14.2, 15.2
D21S11 21q11.2-q21 28, 28 28, 28 28, 28
FGA 4q28 24, 27 24, 27 24, 27
Amelogenin X: p22.1-22.3
X, X X, X X, X
Y: p11.2
The table summarizes the chromosomal localization of each of the investigated loci (AmpFlSTR® Identifiler® Plus PCR Amplification Kit User Guide,
page 3). YM-1 cells after passage 51 show loss of heterozygosity (LOH) in D18S51 locus.
STR short tandem repeat, OL off-ladder, LOH loss of heterozygosity
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cells is illustrated in Fig. 2. Their population doubling time
was 40.66 h. The YM-1 cells were strongly positive of
cytokeratins AE1/AE3 at passage 50 by ICC/IF staining.
This confirmed the epithelial origin of YM-1 cells. Negative
controls were prepared by substituting the blocking buffer
(1 % BSA in PBS solution) with primary antibody; and no
detectable staining was evident (Fig. 5c).
The DNA profiles of YM-1 cell line are shown in Fig. 6.
The genotypes of eight core loci were D5S818 (8, 8),
D13S317 (11, 11), D7S820 (11, 12), D16S539 (10, 12),
vWA (16, 18), TH01 (8, 8), TPOX (12, 12), and CSF1PO
(9, 9) (Fig. 6a).
The genotypes of seven additional loci included in the
AmpFℓSTR® Identifiler® Plus PCR Amplification Kit were
the following: D8S1179 (12, 15), D21S11 (28, 28), D3S1358
(15, 16), D2S1338 (20, 23), D19S433 (14.2, 15.2), D18S51
(10, 14), and FGA (24, 27) (Fig. 6a). When the YM-1 cell line
and donor STR profiles were compared, both had identical
profiles except for D7S820 locus. The donor STR profile
showed the off-ladder allele in D7S820 locus (11, OL geno-
type). Re-STR profiling of YM-1 cell line was performed at
passage 51, and genotype of each locus was determined. The
STR profiles of both passages were identical. Loss of hetero-
zygosity (LOH) was observed in D18S51 locus (Fig. 6b). The
STR profile and chromosomal localization of each of the in-
vestigated loci are summarized in Table 1.
The gender of both donors and our YM-1 cell line were
similar and that was consistent with the female gender of our
patient. STR profiles were compared using DSMZ and ATCC
databases to find the closest match to our samples. Both data-
bases employed a minimum set of loci, eight STR loci plus
amelogenin. Online STR matching analysis with DSMZ and
ATCC databases showed that YM-1 cell line was not
misidentified.
Discussion
The morphology of the YM-1 cells was similar to previously
established cell lines derived from esophageal squamous cell
carcinoma (e.g., HKESC-1 and KYSE-220 cell lines) [20, 21].
However, ESCC cell lines that have been established, so far,
are different from each other in terms of doubling time and
growth characteristics. To address whether YM-1 cells are of
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epithelial origin, expression of cytokeratins was examined by
ICC/IF staining of YM-1 cells at passage 50 with pan-
Cytokeratin (AE1/AE3). AE1/AE3 is a broad spectrum anti
pan-cytokeratin antibody cocktail, which distinguishes epithe-
lial tumors (e.g., ESCC) from non-epithelial tumors (http://
www.novusbio.com/pan-Cytokeratin-Antibody-AE1–AE3_
NBP2-29429.html). This antibody has been used to confirm
the epithelial lineage of esophageal cancer-derived cell lines,
previously [20, 22, 23]. TheYM-1 cells were strongly positive
of cytokeratins AE1/AE3 by ICC/IF (Fig. 5). Therefore, epi-
thelial origin of the YM-1 cells was confirmed.
Recent studies reported that cross-contamination of
mammalian cell lines has formed a major problem in
the scientific community and led to the emergence of
false scientific data [1, 24, 25]. The first report of
cross-contamination of esophageal cancer cell lines goes
back to 1988 by Paul D. van Helden et al. [26]. They
showed that esophageal HCu cell lines have became
cross-contaminated with other cells [26]. Also, they
showed the cell lines HCu 10, 18, 33, 37, and 39 were
genetically identical and were, in fact, subcultures of the
same esophageal cancer cell line [26]. The results of
Boonstra et al. suggested that the TE-7 cell line was
not an esophageal adenocarcinoma, but a squamous cell
carcinoma cell line [1]. Recently, they showed that three
widely used esophageal cancer cell lines were, in fact,
derived from other tumor types [17]. Primary cell cul-
tures undergo a prolonged period of time before the
emergence of an immortalized cell population, and this
is a time, even if a single cell introduced from a separate
cell line would rapidly outgrow the other, leading to a
pure culture of the contaminating cells in four or five
passages [10, 11] (ASN-0002). Therefore, cross-
contamination during or early after establishment of a
new cell line, especially, may result in the worldwide
spread of a misidentified cell line [7, 17].
In this study, the newly established YM-1 cell line, origi-
nated from esophageal squamous cell carcinoma, was evalu-
ated for authenticity using the AmpFℓSTR® Identifiler® Plus
PCR Amplification Kit. This kit has been designated for fo-
rensic application, and all 13 of the required loci for the com-
bined DNA index system (CODIS) loci are included in this kit
[27]. Increasing the number of STR loci included in this kit
will increase the probability that the STR profile of YM-1 cell
line is correctly authenticated as arising from a related donor.
All the loci except the amelogenin gene in this kit are true
tetranucleotide repeats. The length differences among alleles
of a particular locus result from differences in the number of 4-
nt repeat units.
No difference was found between the YM-1 cell line and
donor STR profiles except for D7S820 locus. The STR profile
of the donor showed the off-ladder or microvariant allele in
D7S820 locus (11, OL genotype). Allelic ladders represent the
most common alleles at each locus. Alleles with size outside
allele categories represented in the ladder are known as off-
ladder (OL) alleles [16]. To answer the question whether YM-
1 cells undergo genetic alteration when passage number in-
creases, STR profiling was repeated in cells that were harvest-
ed at passage 51. Surprisingly, allele 10 of the D18S51 locus
was lost (Fig. 6b). The mechanism of the loss of this allele is
unclear; however, it seems that when passage numbers in-
crease, it results in genetic alteration. The results of Parson
et al. suggest that long-term culture of cell lines may alter their
DNA fingerprints [6, 8]. It is accepted within the forensic
science that STR profiling of tumor samples and especially
tumor-derived cell lines is not stable because of loss of het-
erozygosity and microsatellite instability [8, 28].
In AmpFℓSTR® Identifiler® Plus PCR Amplification
Kit, the primers for the amelogenin locus flank a six-
nucleotide deletion within intron 1 of the AMELX.
Amplification results in 107-nt and 113-nt products from
the X and Y chromosomes, respectively. After amplifica-
tion of the AMEL locus, only the related picks of shorter
AMELX fragments (107-nt) were observed and this
means that both DNA donors are individuals with only
X chromosomes, who will usually display a female phe-
notype. This finding was in relevant with the female
gender of our patient.
The DSMZ, together with other databases such as the
ATCC, has generated large comprehensive international
reference STR profile database for human cell lines.
Registered users simply can input their own cell line
STR data to retrieve best matches with authenticated cell
lines listed on the DSMZ and ATCC databases. These
STR profile databases use eight STR loci, plus the
amelogenin marker, recommended by ANSI/ATCC [29].
In this study, for STR matching analysis using DSMZ,
the evaluation value of 0.6 was entered. STR matching
indicated that the YM-1 cell line has a ≤60 % matching.
Also, cell lines showed that shared alleles were not used
in our laboratory during the establishment of our cell
line. A comparison of our STR profile with the ATCC
database showed also that YM-1 cell line had less than
56 % matched with cell lines of this database. Most
studies agree that 80 % similarity is an appropriate
threshold for declaring a match when comparing cell line
profiles [6, 30].
Therefore, the YM-1 cell line is an authentic ESCC cell line
and can be used as in vitro model in medical research. We
suggest that all new established cell lines will be authenticated
by the reference standard method such as STR typing in char-
acterization process. Authentication at this process will pre-
vent the spreading of the misidentified cells and help the re-
producibility and validity of experiments. This study provides
an easy and reliable way for authenticating newly established
cell lines.
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